RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

NCT07735624 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Early Rectal Cancer
Stage I Rectal Cancer
Microsatellite Stable Rectal Carcinoma

Interventions

DRUG: Botensilimab
DRUG: Balstilimab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]